Clinical study of Budesonide powder for inhalation on mild to moderate bronchial asthma
ZHAN Shanshan
Abstract： Objective To evaluate the clinical efifcacy and safety of budesonide powder for inhalation on mild to moderate chronic persistent bronchial asthma. Methods 9 patients with bronchial asthma were selected from April to May in 2011. The patients received budesonide powder for inhalation at the dose of 0.1 mg per puff, 3 puffs each time, and twice a day for 3 months, and using salbutamol aerosol when needed(0.1 mg per puff, no more than 8 puffs a day). Results After treatment, the asthma control test scores went up to 20, and it was signiifcant comparing with the baseline(P<0.05). After treatment for 1 month, the patients′lung functions recovered obviously, and the recovery was continued. The salbutamol needs and asthmatic symptoms decreased signiifcantly from the baseline after 1 month(P<0.05), and continued in the later treatment(P<0.05). Conclusion Budesonide powder for inhalation can improve the asthmatic symptoms and lung functions of mild to moderate chronic persistent bronchial asthmatic patients effectively and safely. The asthma was controlled generally after 1 month of treatment. There was no statisticant variations in terms of lung functions because of little sample.
Keywords：bronchial asthmatreatmentbudesonide
Publication Date：2013-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 38-39,40 )